Medivir was founded in 1988.
In 2018, Medivir conducted a reorganization to focus on the clinical development of the company’s projects.
New data on additive efficacy of fostrox in combination with anti-PD1 in nonclinical tumor models was presented.
Pia Baumann was recruited as new Chief Medical Officer.
Jens Lindberg was appointed as new CEO of Medivir.
Medivir entered into an exclusive licensing agreement with IGM Biosciences for birinapant.
The first patient with HCC started treatment with fostrox (MIV-818) in the phase 1b/2a combination study.
MIV-818 was granted orphan drug designation in USA and the EU.
Yilmaz Mahshid was appointed new CEO of the Company.
Renegotiated agreement with TetraLogic for birinapant, to create improved business development opportunities.
The phase Ia study with MIV-818 was completed.
The birinapant/Keytruda study was ended after a futility analysis.
An investigator-initiated phase I study with birinapant and radiotheraphy was started in patients with head and neck squamous cell carcinoma.
An investigator-initiated phase II study with remetinostat was started in patients with squamous cell carcinoma.
Clinical phase Ia study with MIV-818 was initiated.
Phase II study of birinapant in combination with Keytruda® was initiated in patients with colorectal cancer.
MIV-828 was selected as a candidate drug for the treatment of blood cancer.
The reorganization into a purely clinical drug development company was carried out.
An EGM resolved on a voluntary redemption program comprising a reduction in the share capital for repayment to the shareholders. App. SEK 857.5 million were distributed.
Clinical study of birinapant in combination with Keytruda® in patients with treatment-refractory solid tumors was initiated.
Remetinostat phase II data demonstrated efficacy on skin lesions, reduction of itching and high tolerability in patients with early-stage MF-CTCL.
Groundbreaking top-line results from our initial phase IIa study in the MIV-711 osteoarthritis Project.
Remetinostat and birinapant acquired, forming Medivir’s oncology clinical pipeline.
MIV-818 was selected as a candidate drug (CD) from the company’s project for the treatment of hepatocellular carcinoma.
The subsidiary BioPhausia was divested to Karo Pharma AB.
The exclusive rights to the hepatitis C project, MIV-802, was outlicensed to Trek Therapeutics.
The first oncology project within hepatocellular cancer was generated from the new focus area oncology.
SEK 600 million was transferred to the shareholders through a voluntary redemption program.
MIV-802 was selected as a candidate drug for the treatment of hepatitis C infection.
Simeprevir approved in the EU and Russia for the treatment of adults with chronic hepatitis C.
Olysio and Adasuve launched in Sweden, Norway, Finland and Denmark.
Simeprevir was approved for the treatment of patients with chronic hepatitis C in Japan, Canada and USA.
Registration application for Simeprevir submitted in Japan, USA and Europe.
Positive phase III data reported for Simeprevir, confirming that treatment with Simeprevir in combination with interferon and ribavirin results in high cure rates, a good safety profile, and reduced treatment times.
Global phase III trials of Simeprevir begin.
The North American marketing rights to Xerclear are sold to Meda.
BioPhausia acquired in order to strengthen the commercial platform.
Xerclear approved for sale in certain European markets and the US market.
Phase III trials of Xerclear begin.
Hepatitis C agreement signed with Tibotec/Janssen for Simeprevir.
Mimetrix UK acquired in order to strengthen and expand within the protease sphere.
Medivir listed on the Stockholm Stock Exchange. Collaboration with Abbott begins.
CCS, Clean Chemical Sweden AB, a Sweden-based manufacturer of skincare products, acquired.
Collaboration agreements entered into with Eli Lilly for HIV, and with Wellcome.
Collaboration agreement entered into with American Cyanamid for HIV.